Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of
worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Heart failure (HF) continues to be a major global health problem with a notable impact in
terms of morbidity and mortality and so, in consequence, with a large unmet necessity for …

Background The aims of this study were to:(i) report the baseline characteristics of patients
enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …

Background: Patients with heart failure (HF) and reduced ejection fraction will experience
multiple hospitalizations for heart failure during the course of their disease. We assessed the …